Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 28, 2018

Primary Completion Date

April 1, 2022

Study Completion Date

April 1, 2022

Conditions
Stroke, Acute
Interventions
DEVICE

Transcranial Direct Current Stimulation

Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.

OTHER

Sham Stimulation

Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the cap and electrodes in place, and sham switch moved but without prolonged delivery of electrical stimulation.

Trial Locations (1)

90095

University of California- Los Angeles (UCLA), Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER

NCT03574038 - Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke | Biotech Hunter | Biotech Hunter